top of page
​Algavio is designed to address multiple drivers of inflammatory skin disease:
​
Anti-inflammatory activity
Antimicrobial support
Barrier repair / healing support
Reduce irritation profile
Multi-compound biological activity
​
​
​Algavio proves the platform.​
The platform scales the opportunity.
​
Validated Biological Activity
Preclinical studies show Algavio reduced IL-1a inflammatory signalling and accelerated wound closure in laboratory models, supporting its potential relevance in inflammatory skin conditions.
​
​
Product-Led Dermatology Platform
Algavio is the lead asset. Derma Pharma is using biological datasets, AI-assisted analysis and compound-pathway mapping to support future indication expansion across inflammatory dermatology.
​
​
Regenerative Skin Wellness
bottom of page